Tel Aviv Sourasky Medical Center (Ichilov) has become the first activated clinical site for a Phase 2/3 study of SIL204, an experimental RNA-based therapy designed for patients with locally advanced pancreatic cancer.
The investigational treatment was developed by Silexion Therapeutics and targets one of the most important genetic drivers of pancreatic cancer — mutated KRAS.
KRAS mutations are extremely common in pancreatic cancer. The KRAS protein acts as a molecular switch controlling cell growth and division. When the KRAS gene becomes mutated, this switch can remain abnormally active, continuously sending signals that encourage cancer cells to grow.
For decades, KRAS was considered one of the most difficult targets in oncology.
SIL204 takes a different approach using small interfering RNA, or siRNA.
Rather than attempting to block the KRAS protein after it has already been produced, siRNA technology is designed to interfere with the genetic instructions used by cells to produce the abnormal protein.
In simple terms, the experimental therapy attempts to “silence” mutated KRAS inside cancer cells.
Combining Experimental Therapy With Standard Treatment
The Phase 2/3 study is designed to evaluate SIL204 in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic cancer.
The study uses an unusual dual-delivery strategy. The investigational therapy can be administered directly into the tumor to address the dense tissue surrounding pancreatic tumors, which can make drug penetration difficult, while systemic administration is intended to address cancer beyond the primary tumor.
The Israeli Ministry of Health authorized the study in March 2026, and the institutional ethics committee at Tel Aviv Sourasky Medical Center subsequently approved it.
On July 29, the Ichilov site was formally activated and cleared to begin screening patients. Additional clinical centers in Israel and Germany were also being prepared to participate.
The development is important because pancreatic cancer remains one of the most difficult cancers to treat, particularly when surgery is not immediately possible.
At the same time, patients should understand the distinction between an approved therapy and a clinical trial.
SIL204 remains an investigational treatment. Its safety and effectiveness must be demonstrated in clinical trials before it can potentially become part of routine pancreatic cancer care.
Nevertheless, moving the technology into a Phase 2/3 clinical study represents an important step from laboratory research toward potential clinical application.
If you have pancreatic cancer and need help obtaining a consultation with Israeli oncologists, a second medical opinion, or information about diagnosis and treatment options in Israel, contact Sapir Medical Clinic. Our team can help review your medical documents and organize consultations, examinations, and treatment with Israeli specialists.